Your browser doesn't support javascript.
loading
Combined Cohesin-RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes.
Ochi, Yotaro; Kon, Ayana; Sakata, Toyonori; Nakagawa, Masahiro M; Nakazawa, Naotaka; Kakuta, Masanori; Kataoka, Keisuke; Koseki, Haruhiko; Nakayama, Manabu; Morishita, Daisuke; Tsuruyama, Tatsuaki; Saiki, Ryunosuke; Yoda, Akinori; Okuda, Rurika; Yoshizato, Tetsuichi; Yoshida, Kenichi; Shiozawa, Yusuke; Nannya, Yasuhito; Kotani, Shinichi; Kogure, Yasunori; Kakiuchi, Nobuyuki; Nishimura, Tomomi; Makishima, Hideki; Malcovati, Luca; Yokoyama, Akihiko; Takeuchi, Kengo; Sugihara, Eiji; Sato, Taka-Aki; Sanada, Masashi; Takaori-Kondo, Akifumi; Cazzola, Mario; Kengaku, Mineko; Miyano, Satoru; Shirahige, Katsuhiko; Suzuki, Hiroshi I; Ogawa, Seishi.
Afiliação
  • Ochi Y; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kon A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Sakata T; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Nakagawa MM; Laboratory of Genome Structure and Function, Research Division for Quantitative Life Sciences, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan.
  • Nakazawa N; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kakuta M; Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Kyoto, Japan.
  • Kataoka K; Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Koseki H; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Nakayama M; Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
  • Morishita D; Laboratory of Medical Omics Research, Department of Frontier Research and Development, Kazusa DNA Research Institute, Kisarazu, Japan.
  • Tsuruyama T; Chordia Therapeutics Inc., Kanagawa, Japan.
  • Saiki R; Department of Drug and Discovery Medicine, Pathology Division, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Yoda A; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Okuda R; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Yoshizato T; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Yoshida K; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Shiozawa Y; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Nannya Y; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kotani S; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kogure Y; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kakiuchi N; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Nishimura T; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Makishima H; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Malcovati L; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Yokoyama A; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Takeuchi K; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Sugihara E; Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Sato TA; Tsuruoka Metabolomics Laboratory, National Cancer Center, Yamagata, Japan.
  • Sanada M; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Takaori-Kondo A; Research and Development Center for Precision Medicine, University of Tsukuba, Ibaraki, Japan.
  • Cazzola M; Research and Development Center for Precision Medicine, University of Tsukuba, Ibaraki, Japan.
  • Kengaku M; Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Miyano S; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Shirahige K; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Suzuki HI; Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Ogawa S; Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Kyoto, Japan.
Cancer Discov ; 10(6): 836-853, 2020 06.
Article em En | MEDLINE | ID: mdl-32249213
ABSTRACT
STAG2 encodes a cohesin component and is frequently mutated in myeloid neoplasms, showing highly significant comutation patterns with other drivers, including RUNX1. However, the molecular basis of cohesin-mutated leukemogenesis remains poorly understood. Here we show a critical role of an interplay between STAG2 and RUNX1 in the regulation of enhancer-promoter looping and transcription in hematopoiesis. Combined loss of STAG2 and RUNX1, which colocalize at enhancer-rich, CTCF-deficient sites, synergistically attenuates enhancer-promoter loops, particularly at sites enriched for RNA polymerase II and Mediator, and deregulates gene expression, leading to myeloid-skewed expansion of hematopoietic stem/progenitor cells (HSPC) and myelodysplastic syndromes (MDS) in mice. Attenuated enhancer-promoter loops in STAG2/RUNX1-deficient cells are associated with downregulation of genes with high basal transcriptional pausing, which are important for regulation of HSPCs. Downregulation of high-pausing genes is also confirmed in STAG2-cohesin-mutated primary leukemia samples. Our results highlight a unique STAG2-RUNX1 interplay in gene regulation and provide insights into cohesin-mutated leukemogenesis.

SIGNIFICANCE:

We demonstrate a critical role of an interplay between STAG2 and a master transcription factor of hematopoiesis, RUNX1, in MDS development, and further reveal their contribution to regulation of high-order chromatin structures, particularly enhancer-promoter looping, and the link between transcriptional pausing and selective gene dysregulation caused by cohesin deficiency.This article is highlighted in the In This Issue feature, p. 747.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Cromatina / Proteínas Cromossômicas não Histona / Proteínas de Ciclo Celular / Subunidade alfa 2 de Fator de Ligação ao Core Tipo de estudo: Etiology_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Cromatina / Proteínas Cromossômicas não Histona / Proteínas de Ciclo Celular / Subunidade alfa 2 de Fator de Ligação ao Core Tipo de estudo: Etiology_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article